February 27th 2024
The new approval is supported by the phase 3 Study 4030, which evaluated the efficacy, safety, and tolerability profile of Biktarvy in a broad range of people with HIV-1 with or without pre-existing NRTI resistance, including those with the M184V/I resistance.
September 14th 2023
Risks and Liabilities in Pharmacy Practice
1.0 Credit / Law
View More
Navigating Approved Pre-exposure Prophylaxis (PrEP) Options for HIV Prevention: The Expanding Role of Pharmacists as Patient Educators and Advocates (Pharmacy Technician Credi...
2.0 Credits / HIV/AIDS
View More
Navigating Approved Pre-exposure Prophylaxis (PrEP) Options for HIV Prevention: The Expanding Role of Pharmacists as Patient Educators and Advocates (Pharmacist Credit)
2.0 Credits / HIV/AIDS
View More
Background and Key Concepts in Biosimilars: Improving Awareness and Addressing Common Concerns
1.0 Credit / Law
View More
Clinical Conversations With the Cancer Care Team: Striving for Equitable Access to Oral Anticancer Medications
1.5 Credits / Law, Oncology
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More